RGEN News and Press, Repligen Corporation From 12/10/20

WALTHAM, Mass., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ: RGEN) today announced the closing of its previously announced underwritten public offering of an aggregate of 1.725 million shares of its common stock at a public offering price of $181 per share for gross proce...

Founded and led for over 30 years by physician-scientists, Regeneron (RGEN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases, notes Ingrid Hendershot, a leading value-oriented money manager and editor of Hendershot Investments. For...

EC Mergers & Acquisitions advised ARTeSYN on its Sale to Repligen NEW YORK , Dec. 8, 2020 /PRNewswire/ -- EC Mergers & Acquisitions ("EC M&A") is pleased to confirm the sale of ARTeSYN BioSolutions ("ARTeSYN") ARTeSYN is a manufacturer...

Repligen (RGEN) has priced its public offering of 1.5M common shares at $181/share.Expected proceeds are ~$271.5M.Underwriters' over-allotment is an additional 225K shares.Net proceeds will be used for working capital and other general corporate purposes.Closing date is December 10. For fur...

Repligen ([[RGEN]] -0.3%) has commenced an underwritten public offering of 1.5M shares of its common stock.Underwriters option to purchase up to an additional 225k shares.Net proceeds to be used for working capital and other general corporate purposes. For further details see: Repligen ...

Repligen is a "pick-and-shovel" play in the bioprocessing industry. Repligen heavily invests in single-use products for use in downstream continuous manufacturing processes, which are two of the latest trend in the bioprocessing industry. COVID-19 programs accounted for appro...

Horizon Therapeutics (HZNP) is a specialty and generic drug manufacturing company that relies on RGEN to build out its pipeline of drugs. The stock has taken off this year as two of its blockbuster drugs got approved by the FDA. However, the stock recently slumped despite reporting strong thi...

Shares of bioprocessing technology company Repligen (NASDAQ: RGEN) soared 12.9% in October according to data provided by S&P Global Market Intelligence . The move comes in a remarkable year for the company as its stock has more than doubled so far in 2020. The reason? Si...

Repligen Corporation (RGEN) Q3 2020 Earnings Conference Call November 05, 2020, 08:30 AM ET Company Participants Sondra Newman - Global Head of Investor Relations Tony Hunt - President and Chief Executive Officer Jon Snodgres - Chief Financial Officer Conference Call Participants Dan Arias - ...

Repligen (RGEN): Q3 Non-GAAP EPS of $0.40; GAAP EPS of $0.27 beats by $0.11.Revenue of $94.06M (+35.4% Y/Y) beats by $7.61M.Press Release For further details see: Repligen EPS beats by $0.11, beats on revenue